Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites.
about
Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promiseNeuropharmacology of venlafaxine.Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers.Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorderSerotonin and beyond: therapeutics for major depression.Venlafaxine-induced depression of wind-up activity in mononeuropathic rats is potentiated by inhibition of brain 5-HT1A receptor expression in vivo.Chronic serotonin-norepinephrine reuptake transporter inhibition modifies basal respiratory output in adult mouse in vitro and in vivo.Different alpha(2) adrenoceptor subtypes control noradrenaline release and cell firing in the locus coeruleus of wildtype and monoamine oxidase-A knockout mice.Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers.Inhibition by venlafaxine of the increase in norepinephrine output in rat prefrontal cortex elicited by acute stress or by the anxiogenic drug FG 7142.Antidepressant-like effect of different estrogenic compounds in the forced swimming test.Electrophysiological evidence for the tonic activation of 5-HT(1A) autoreceptors in the rat dorsal raphe nucleus.Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors.Study of Sex Differences in Duloxetine Efficacy for Depression in Transgenic Mouse Models.Spatiotemporal interaction of alpha(2) autoreceptors and noradrenaline transporters in the rat locus coeruleus: implications for volume transmission.Dual serotonin and noradrenaline reuptake inhibitors: Focus on their differences.Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs).Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects
P2860
Q24657417-BA72E761-B0FE-41CB-BDD4-88381019992EQ34093686-DF29BDF6-78D5-428A-97AB-3C2F31A8E246Q34502908-8E56D309-FDC0-4A45-BE76-A5ED47192008Q35205431-4B8ED2FA-4B2C-44BE-A53E-1CE6E3E8F2F7Q38084600-D9B0933F-6D55-400B-82AA-A90FC97009CBQ40542886-23EF6ABE-322F-4E41-882C-776FA26719C2Q41790115-3DAFB264-7E4E-4564-97B1-266D2ECD8B94Q42444604-8CED9435-2C8E-4986-9096-049A7B3EAB8EQ43558688-1C57A869-33D9-48FD-BB90-537C2C2EC94DQ44048458-1615AC9C-6659-4FA9-AF6B-A6791F6A2545Q44362484-6BC378BC-CA37-4C61-8E9E-798E903B56B5Q44883680-AB618E1F-DDF8-401F-BB36-B57337D56A2EQ45176540-1F224720-5651-42DE-9699-45D13C47D80AQ46913603-B9CF4048-8A9C-4414-BEDC-288AFEEDD3E4Q47142267-13BE5080-2873-45DB-BE0F-372F1D5F4696Q51400728-21986193-28C6-4E02-840A-369CEF595055Q51922808-212B14F8-B8FC-48D7-9ACE-89E587C3B3D0Q55421497-86E06B09-0AD0-4958-A144-971730CAD4A6Q57550294-B9B620FE-E293-46C3-943C-7F3ED292EFE8
P2860
Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Venlafaxine: discrepancy betwe ...... d affinity for reuptake sites.
@en
Venlafaxine: discrepancy betwe ...... d affinity for reuptake sites.
@nl
type
label
Venlafaxine: discrepancy betwe ...... d affinity for reuptake sites.
@en
Venlafaxine: discrepancy betwe ...... d affinity for reuptake sites.
@nl
prefLabel
Venlafaxine: discrepancy betwe ...... d affinity for reuptake sites.
@en
Venlafaxine: discrepancy betwe ...... d affinity for reuptake sites.
@nl
P2093
P2860
P1433
P1476
Venlafaxine: discrepancy betwe ...... d affinity for reuptake sites.
@en
P2093
Debonnel G
de Montigny C
P2860
P304
P356
10.1002/(SICI)1098-2396(19990601)32:3<198::AID-SYN6>3.0.CO;2-2
P577
1999-06-01T00:00:00Z